Navigation Links
Fate Therapeutics announces creation of small molecule platform for commercial-scale reprogramming
Date:10/18/2009

La Jolla, CA October 18, 2009 Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming. The discoveries, which were made by Sheng Ding, Ph.D. under a research collaboration between Fate Therapeutics and The Scripps Research Institute (TSRI), represent a more than 200-fold improvement in reprogramming efficiency and reduce the reprogramming period to two weeks as compared to methods using only the four reprogramming factors (Oct 3/4, Sox2, Klf4 and c-Myc). This latest advancement has broad implications for the creation of "pharmaceutical grade" iPSCs, reprogrammed cells that can be produced without genetic modification at commercial scale quantity, quality and consistency and continues to bolster the leadership position of Fate Therapeutics in industrialized iPSC technology. The Company is developing minimally invasive techniques for reprogramming and differentiation and has exclusively in-licensed from TSRI and the Whitehead Institute for Biomedical Research a intellectual property portfolio related to iPSC technology dating back to November 2003.

"While recent studies have reported improved methods of reprogramming, those techniques have relied on further genetic manipulation or have not otherwise addressed a fundamental reprogramming challenge that iPSC generation is still a very slow and inefficient process and results in a heterogeneous population of cells," said Paul Grayson, president & CEO of Fate Therapeutics. "Once again, Dr. Ding and his team are the first group to clear yet another major hurdle required for the widespread commercial use of iPSCs for drug discovery and patient therapies."

The findings of Dr. Ding and his colleagues are published today in the Advanced Online edition of the scientific journal Nature Methods. As compared to using the four reprogramming factors of Oct 3/4, Sox2, Klf4 and c-Myc alone, Dr. Ding discovered a combined chemical approach that dramatically improves (> 200 fold) the generation of iPSCs from human fibroblasts within two weeks of retroviral transduction. The iPSC colonies generated by the Ding team using a 3-compound cocktail could be stably expanded over the long term (20+ passages), closely resembled human embryonic stem cells in terms of morphology and pluripotency marker expression and could be differentiated into derivatives of all the three germ layers both in vitro and in vivo.

"Once we achieved reprogramming with cell-penetrating proteins, we targeted certain biological pathways that might improve speed and efficiency so as to enable the commercial scale production of patient-specific iPSCs for medical use," said Dr. Ding, associate professor of TSRI and scientific founder of Fate Therapeutics. "When combined with non-viral, non-DNA based methods for iPSC generation, we believe these discoveries create a powerful platform for safer, more efficient reprogramming of human somatic cells."

Earlier this year, under a research collaboration with Fate Therapeutics and TSRI, Dr. Ding and his team of scientists became the first group to generate iPSCs using non-viral, non-DNA based reprogramming methods. Instead of inserting the reprogramming factors of Oct 3/4, Sox2, Klf4 and c-Myc with DNA-based methods, such as viruses or plasmids, the scientists engineered and used recombinant proteins to reprogram cells without genetic modifications. The scientists found that those reprogrammed embryonic-like cells dubbed "protein -induced pluripotent stem cells" or "piPSCs" from fibroblasts behave indistinguishably from classic embryonic stem cells in their molecular and functional features, including differentiation into various cell types, such as beating cardiac muscle cells, neurons, and pancreatic cells.


'/>"/>

Contact: Cory Tromblee
ctromblee@macbiocom.com
617-571-7220
MacDougall Biomedical Communications, Inc.
Source:Eurekalert

Related biology news :

1. AACR, NCI and EORTC to host molecular targets and cancer therapeutics conference
2. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
3. Amarna Therapeutics B.V. and TNO announce SVac research and development partnership
4. Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics
5. NIH announces new program to develop therapeutics for rare and neglected diseases
6. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
7. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
8. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
9. A novel target for therapeutics against Staph infection
10. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
11. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
Breaking Biology News(10 mins):
(Date:7/26/2017)... ... July 26, 2017 , ... Vincent R. Burton, MBBS, FRCA, ... licensed by the Bahamas’ National Stem Cell Ethics Committee (NSCEC). , Dr. Burton ... the West Indies. He went on to complete residency training in the United Kingdom ...
(Date:7/26/2017)... ... July 25, 2017 , ... Avery Products ... that enable short-run digital printing, is proud to announce that it has won ... Wizard online software available at avery.com/GHS . The products were recently honored ...
(Date:7/26/2017)... , ... July 25, 2017 , ... ... and manufacturing services that are necessary in the preparation and development of human ... biorepository facility operates under the US Food and Drug Administration’s (FDA) Current Good ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... company for the improvement of crop productivity and economics for the food, feed ... The scope of the agreement includes the research and development of microbiome-based seed ...
Breaking Biology Technology: